

From the Chief Medical Officer
Professor Sir Michael McBride



HSS(MD)37/2026

FOR ACTION

Chief Executives, Public Health Agency/HSC
Trusts/NIAS
Chief Operating Officer, SPPG
GP Medical Advisers, SPPG
All General Practitioners and GP Locums (*for
onward distribution to practice staff and
Community Pharmacies*)
OOH Medical Managers (*for onward distribution to
staff*)

Castle Buildings
Stormont Estate
Belfast BT4 3SQ
Tel: 028 90 520653
Email: cmooffice@health-ni.gov.uk

Your Ref:
Our Ref: HSS(MD)37/2026
Date: 2 October 2026

**PLEASE SEE ATTACHED FULL CIRCULATION
LIST**

Dear Colleague

**NATIONAL PATIENT SAFETY ALERT – LEVEMIR® (INSULIN DETEMIR)
FLEXPEN® 100UNITS/ML SOLUTION FOR INJECTION 3ML PRE-FILLED PENS
AND LEVEMIR® (INSULIN DETEMIR) PENFILL® 100UNITS/ML SOLUTION FOR
INJECTION 3ML CARTRIDGES**

This alert is for action by for all organisations involved in prescribing and dispensing Levemir® (insulin detemir) products.

This is a safety critical and complex National Patient Safety Alert. Implementation should be led by an executive lead (or equivalent role in organisations without executive boards) and supported by clinical leaders in Diabetes and Endocrinology, GP Practices, and Pharmacy.

Actions required with immediate effect:

Clinicians and prescribers of Levemir® must:

- Not initiate patients on any Levemir® product.

Community pharmacists must:

- When presented with prescriptions for Levemir® products, after ensuring the patient has sufficient insulin, refer patients back to their prescriber, highlighting the need to switch to an alternative insulin due to the imminent Levemir® discontinuation.

As soon as possible and no later than 30th November 2026:

Clinicians and prescribers of Levemir® must:

- In line with locally agreed plans, implement insulin switches for all existing Levemir® patients in line with the [clinical guidance](#) (see Additional information below).
- Local teams should ensure that they have checked the current supply overview ^{NOTE A} of alternative insulins and aim to diversify prescribing across available alternatives to reduce the risk of precipitating a supply disruption of alternative products (see Additional information).
- In addition to consulting the clinical guidance, when prescribing alternatives, consider manual dexterity, vision, and whether additional support is required for administration, and:
 - ensure that all patients/carers are counselled on dose to be administered, provided with training on the use of their new device, as well as appropriate ancillaries, including signposting to training videos; and
 - advise patients that closer monitoring of blood glucose levels is required initially, and their insulin dose may need to be adjusted.
- Seek advice from specialist diabetes teams where required.

Summary of identified issue

This alert is to supplement previous communications issued:

- Medicine Supply Notification (Our ref: MPS 3386) (NHS England ref: MSN/2025/036) – issued on 16th June 2025;
- Medicine Supply Notification (Our ref: Updated MPS 3386) (NHS England ref: MSN/2025/036U) – issued on 14th August 2025; and
- Medicine Supply Notification (Our ref: MPS 3495) (MSN/2025/036U2) – issued on 15th April 2026.

Levemir® (insulin detemir) FlexPen® 100units/ml solution for injection 3ml pre-filled pens and Levemir® (insulin detemir) Penfill® 100units/ml solution for injection 3ml cartridges are being discontinued from end of December 2026 with stocks anticipated to be exhausted by this date.

Levemir® is a long-acting insulin analogue with a prolonged duration of effect used as a basal insulin. It is licensed for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above. It can be used alone as the basal insulin or in combination with bolus insulin. It can also be used in combination with oral antidiabetic medicinal products and/or GLP-1 receptor agonists.

A range of alternative insulins from other suppliers are available. ^{NOTE A}

Please refer to [the SPS Medicines Supply Tool entry for the discontinuation of Levemir® products](#) for an overview of the supply situation and up to date supply stock overview of recommended insulins. The Medicines Supply Tool should be monitored regularly, as supply capabilities of alternative options remain subject to change.

Additional information

For advice on switching patients on Levemir® to a suitable alternative, please refer to the clinical guidance that has been produced by clinical experts.

Alternative insulins NOTE A:

Insulin glargine U100 (Long acting):

- Abasaglar® KwikPen® and Abasaglar® cartridges. Please note: these cannot support increased demand.
- Lantus® SoloStar® and Lantus® cartridges
- Semglee® pre-filled pens (biosimilar)

Insulin glargine U300 (Ultralong acting):

- Toujeo® SoloStar® and Toujeo® DoubleStar®

Please note: as insulin glargine is available in two strengths, these products must be prescribed by brand to minimise the risk of product mis-selection.

Insulin degludec (Ultralong acting):

- Tresiba® U100 cartridges and Tresiba® U200 FlexTouch®

Human isophane insulin (intermediate acting):

- Humulin® I KwikPen® and Humulin® I cartridges. Please note: these cannot support increased demand.

Notes:

NOTE A: Refer to the [Levemir® discontinuation entry on the SPS website](#) for an up-to-date supply stock overview.

References

1. [Clinical Guideline: Discontinuation of Levemir®](#)
2. [BNF Insulin detemir](#)
3. [BNF Insulin preparations](#)
4. [NICE guidance: Type 1 diabetes in adults \(insulin therapy\)](#)
5. [NICE CKS- Insulin therapy in type 1 diabetes](#)
6. [NICE CKS- Insulin therapy in type 2 diabetes](#)
7. [SmPC Levemir®](#)
8. [SmPC Lantus®](#)
9. [SmPC Toujeo®](#)
10. [SmPC Abasaglar®](#)

11. [SmPC Semglee®](#)
12. [SmPC Tresiba®](#)
13. [SmPC Humulin® I](#)
14. [SPS Medicines Supply Tool entry for the discontinuation Levemir® products](#)

Yours sincerely



PROFESSOR SIR MICHAEL McBRIDE
Chief Medical Officer



PROFESSOR CATHY HARRISON
Chief Pharmaceutical Officer

Circulation List

Director of Public Health/Medical Director, Public Health Agency (*for onward distribution to all relevant health protection staff*)
Assistant Director Public Health (Health Protection), Public Health Agency
Director of Nursing, Public Health Agency
Assistant Director of Pharmacy and Medicines Management, SPPG (*for onward distribution to SPPG Pharmacy and Medicines Management Team and community pharmacists*)
Directors of Pharmacy HSC Trusts
Director of Social Care and Children, SPPG
Family Practitioner Service Leads, SPPG (*for cascade to GP Out of Hours services*)
Medical Directors, HSC Trusts (*for onward distribution to all Consultants, Occupational Health Physicians and School Medical Leads*)
Nursing Directors, HSC Trusts (*for onward distribution to all Community Nurses, and Midwives*)
Directors of Children's Services, HSC Trusts
RQIA (*for onward transmission to all independent providers including independent hospitals*)
Regional Medicines Information Service, Belfast HSC Trust
Regional Pharmaceutical Procurement Service, Northern HSC Trust
Professor Kenda Crozier, Head of School of Nursing and Midwifery QUB
Andrea Shepherd, Head of School of Nursing, Ulster University
Ann Kerrin, Head of HSC Clinical Education Centre
Stephanie Foster, Open University
Professor Paul McCarron, Head of School of Pharmacy and Pharmaceutical Sciences, Ulster University
Professor Gavin Andrews, Head of School, School of Pharmacy, QUB
Postgraduate Pharmacy Dean, NI Centre for Pharmacy Learning and Development, QUB
Michael Donaldson, Head of Dental Services, SPPG (*for distribution to all General Dental Practitioners*)
Raymond Curran, Head of Ophthalmic Services, SPPG (*for distribution to Community Optometrists*)
Trade Union Side
Clinical Advisory Team
Louise McMahon, Director of Integrated Care, SPPG
Prof Camille Harron, NIMDTA
Prof Pascal McKeown, QUB
Prof Alan Smyth, QUB
Prof Peter Bazira, Head of Medical School, UU
Dr Kathy Cullen, Director of the Centre for Medical Education at QUB
Michelle Tennyson, Allied Health Professional, DoH
Lead Allied Health Professional HSC Trusts
Head of School, UU
Glynis McMurtry - Professional Head of Pharmacy GP Federations (*for onward distribution to GP Pharmacists*)

.....
This letter is available on the Department of Health website at
<https://www.health-ni.gov.uk/topics/professional-medical-and-environmental-health-advice/hssmd-letters-and-urgent-communications>
.....